ghrs.q Archives • ShroomStocks.ca

Investing is a trip

Recent Posts

BioNxt Solutions (BNXT.C) to spark marketing as ODF human studies begin
Revive Therapeutics (RVV.CN) updates on psilocybin study for methamphetamine use
Lophos Pharma (MESC.C) now readies for natural and synthetic peyote production
Peyote at the ready: Lophos Holdings (MESC.C) expands license, lays out product specs
Peyote at the ready: Lophos Holdings (MESC.C) expands license, lays out product specs
Optimi Health (OPTI.C) transforming psychedelic treatment and wellness
Bionxt Solutions (BNXT.C) shows how pivots don’t have to mean resets
Bionxt Solutions (BNXT.C) shows how pivots don’t have to mean resets
Lophos Pharmaceuticals (MESC.C) expands licensing to include just about all the drugs
Lophos Pharmaceuticals (MESC.C) expands licensing to include just about all the drugs
Reveive Therapeutics (RVV.C) finds multiple research options moving forward
Cannabis memory lane: Who’s sticking it out, who’s dead and dying

Search for:

Post date
February 2, 2022
Posted by
Vishal Toora
Posted in field trip ketamine stock, GH research, ghrs.q, investments, Mushrooms, mushshrooms, numi stock, NUMI.T, PSIL, Psychedelic Stocks, Psychedelics, PSYK, seelos therapeutics, shroom-stocks, shrooms, stock market, stocks, Today's Analysis
Comments
0